BAY1747846
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Contrast Enhancement in Magnetic Resonance Imaging
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Trial Timeline
Oct 12, 2021 → Jul 14, 2022
NCT ID
NCT05061979About BAY1747846
BAY1747846 is a phase 1 stage product being developed by Bayer for Contrast Enhancement in Magnetic Resonance Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT05061979. Target conditions include Contrast Enhancement in Magnetic Resonance Imaging.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05061979 | Phase 1 | Completed |
Competing Products
11 competing products in Contrast Enhancement in Magnetic Resonance Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-9231 + Gadobutrol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Gadoquatrane (BAY1747846) | Bayer | Phase 3 | 74 |
| GBCAs | Bayer | Pre-clinical | 20 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoxetic acid disodium (Primovist, BAY86-4873) | Bayer | Approved | 82 |
| BAY1747846 + Matching placebo | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo | Bayer | Phase 1 | 30 |
| Gadobutrol (Gadavist/Gadovist, BAY86-4875) | Bayer | Pre-clinical | 20 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Magnevist + Dotarem + Gadovist | Guerbet | Pre-clinical | 15 |